Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$99.30M+1614.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark L. Baum
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 373
- Beta
- 0.24
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.09
Financials
Revenue
$99.30M+1614.1%Net Income
$9.76MEBITDA
$17.49MFree Cash Flow
$-8.99MEPS (diluted)
$0.25Shares Outstanding (diluted)
38.53M+103.6%Operating Expenses
$63.43MCash & Debt
$75.34MReturn of Capital
$0.00Revenue by Segment (annual)
$272.30MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $272.30M | $-5.14M | $-0.14 |
| 2024 | $199.61M | $-17.48M | $-0.49 |
| 2023 | $130.19M | $-24.41M | $-0.75 |
| 2022 | $88.59M | $-14.09M | $-0.51 |
| 2021 | $72.48M | $-18.01M | $-0.69 |
| 2020 | $48.87M | $-3.36M | $-0.13 |
| 2019 | $51.16M | $168.0K | $0.01 |
| 2018 | $41.37M | $14.63M | $0.67 |
| 2017 | $26.77M | $-11.98M | $-0.60 |
| 2016 | $19.94M | $-19.09M | $-1.50 |
| 2015 | $9.72M | $-15.90M | $-1.66 |
| 2014 | $1.66M | $-10.12M | $-1.11 |
| 2013 | $10.0K | $-7.64M | $-0.88 |
| 2012 | $100.0K | $-5.38M | $-1.24 |
Valuation
HROWhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (15)
- Newsglobenewswire.com·10d ago·Neutral
Harrow to Participate in Two Investor Conferences in November NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following investor conferences in November: Craig-Hallum 17 th Annual Alpha Select Conference Format: 1x1 investor meetings Date: Tuesday, November 17, 2026 Location: New York, NY 2026 Jefferies Global Healthcare Conference For…
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript Harrow, Inc. ( HROW ) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the Board & Founder Andrew Boll - President, CFO & Chief Accounting Officer Patrick Sullivan - Chief Commercial Officer Amir Shojaei - Chief Scientific Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research D…
View source ↗ - Newsmarketbeat.com·12d ago·Negative
Harrow Q3 Earnings Call Highlights Harrow NASDAQ: HROW reported record third-quarter revenue and reaffirmed its full-year sales forecast, but sharply reduced its adjusted earnings outlook as lower-than-expected margins and accelerated spending weighed on profitability.
View source ↗ - Newszacks.com·13d ago·Neutral
Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·13d ago·Negative
Harrow (HROW) Q3 Earnings Lag Estimates Harrow (HROW) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.33 per share a year ago.
View source ↗ - Newszacks.com·20d ago·Neutral
Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy? Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Harrow Launches HarrowRx Platform NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access pharmacy platform that enables eyecare professionals to access Harrow's entire portfolio directly within the electronic medical record (EMR) systems they already use.
View source ↗ - Newsseekingalpha.com·24d ago·Negative
Harrow's Top Two Drugs Alone Can Justify Its Current Valuation Harrow trades at a 52-week low due to management miscommunication and short-term revenue volatility, but its fundamentals remain robust. Vevye and Iheezo, Harrow's flagship drugs, both address large, underpenetrated markets and are positioned for significant growth as coverage expands and pricing stabilizes. Temporary headwinds, including inventory dynamics and coverage transitions, have obscured accelerating prescription trends and
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026 NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2026, on Monday, November 9, 2026, after the market close.
View source ↗ - Newszacks.com·44d ago·Neutral
Do Options Traders Know Something About Harrow Stock We Don't? Investors need to pay close attention to HROW stock based on the movements in the options market lately.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: American Academy of Optometry's (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim…
View source ↗ - Newsglobenewswire.com·94d ago·Neutral
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
Harrow Q2 Earnings Call Highlights Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.
View source ↗ - Newszacks.com·104d ago·Negative
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago.
View source ↗
Earnings
Mon, Mar 1(in 3 months)
Consensus estimate $0.56 per share
Typical surprise -79.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$0.25 vs $0.19beat
- Mon, Aug 10$-0.46 vs $-0.18miss
- Mon, May 11$-0.74 vs $-0.43miss
- Mon, Mar 2$0.18 vs $0.40miss
- Mon, Nov 10$0.03 vs $0.22miss
- Mon, Aug 11$0.14 vs $0.01beat
Estimates and results for HROW via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HROW officers and directors.
- Bought
- $3.1m
- Sold
- $12.4m
16 trades
18 trades
- Shojaei Amirsold
- Graves Adrienne Lbought
- Silvernail Lauren Pbought
- Baum Mark Lbought
- Boll Andrew R.bought
- Opaleye Management Inc.sold
- Opaleye Management Inc.sold
- Opaleye Management Inc.sold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HROW.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
